Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Daniel Bandari, Meagan Adamson, Michelle Bowman, Amparo Gutierrez, Amod Athavale, Bhagyashree Oak, Nandini Hadker, Filipe Branco, Caroline Geremakis, James B. Lewin & Sai L. Shankar. (2023) Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment. Journal of Medical Economics 26:1, pages 1507-1518.
Read now
Read now
Hiba EL Masri, Treasure M McGuire, Mieke L van Driel, Helen Benham & Samantha A Hollingworth. (2022) Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review. Patient Preference and Adherence 16, pages 2609-2637.
Read now
Read now
Sajida Sabsabi, Elio Mikhael, Georges Jalkh, Gabrielle Macaron & Mary Rensel. (2022) Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Preference and Adherence 16, pages 1307-1319.
Read now
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Emma van Eijndhoven, Michelle Brauer, Rebecca Kee, Joanna MacEwan, Lisa Mucha, Schiffon L. Wong, Adeline Durand & Jason Shafrin. (2020) Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis. Journal of Medical Economics 23:5, pages 474-483.
Read now
Read now
Dirk Deleu, Beatriz Canibaño, Boulenouar Mesraoua, Gholamreza Adeli, Mohamed S. Abdelmoneim, Yasir Ali, Osama Elalamy, Gayane Melikyan & Amir Boshra. (2020) Management of relapsing–remitting multiple sclerosis in Qatar: an expert consensus. Current Medical Research and Opinion 36:2, pages 251-260.
Read now
Read now
Chao Chen, Ning Wu & Crystal Watson. (2018) Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. ClinicoEconomics and Outcomes Research 10, pages 723-730.
Read now
Read now
Catherine Bottomley, Andrew Lloyd, Gary Bennett & Nicholas Adlard. (2017) A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. Journal of Medical Economics 20:8, pages 863-870.
Read now
Read now
Articles from other publishers (21)
Edward J. D. Webb, David Meads, Ieva Eskytė, Helen L. Ford, Hilary L. Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue H. Pavitt, Klaus Schmierer & Ana Manzano. (2023) Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices. The Patient - Patient-Centered Outcomes Research.
Crossref
Crossref
Jeri Burtchell, Daisy Clemmons, Joann Clemmons, Tim Sabutis, Adeline Rosenberg, Jennifer Graves, Michael L. Sweeney, John Kramer, Marina Ziehn, Brandon Brown, Jamie L. Weiss & Ahmed Z. Obeidat. (2022) A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies. Neurology and Therapy 11:3, pages 955-979.
Crossref
Crossref
Sara Simblett, Mark Pennington, Matthew Quaife, Evangelia Theochari, Patrick Burke, Giampaolo Brichetto, Julie Devonshire, Simon Lees, Ann Little, Angie Pullen, Amanda Stoneman, Sarah Thorpe, Janice Weyer, Ashley Polhemus, Jan Novak, Erin Dawe-Lane, Daniel Morris, Magano Mutepua, Clarissa Odoi, Emma Wilson & Til Wykes. (2022) Key Drivers and Facilitators of the Choice to Use mHealth Technology in People With Neurological Conditions: Observational Study. JMIR Formative Research 6:5, pages e29509.
Crossref
Crossref
Ovidio Fernández, Martín Lázaro-Quintela, Guillermo Crespo, Diego Soto de Prado, Álvaro Pinto, Laura Basterretxea, Alfonso Gómez de Liaño, Olatz Etxaniz, Sara Blasco, Clara Gabás-Rivera, Susana Aceituno, Virginia Palomar & Carlos Polanco-Sánchez. (2022) Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists. Frontiers in Oncology 11.
Crossref
Crossref
Rahil Bahadori, Parvin Ehteshamzadeh, Zahra Eftekhar Saadi & Reza Pasha. (2021) Comparison of the Effects of the Choice Theory and Behavioral Activation Therapies with and Without Guided Imagery Rescripting on the Adversity Quotient and Cognitive Emotion Regulation of MS Patients in Ahvaz, Iran. Journal of Kermanshah University of Medical Sciences 25:4.
Crossref
Crossref
L.A. Visser, S.P.I. Huls, C.A. Uyl-de Groot, E.W. de Bekker-Grob & W.K. Redekop. (2021) An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries. Journal of the Neurological Sciences 428, pages 117587.
Crossref
Crossref
Yasuo Sugitani, Kyoko Ito & Shunsuke Ono. (2021) Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan. Frontiers in Pharmacology 12.
Crossref
Crossref
Andres G. Barboza, Edgar Carnero Contentti, Maria Celeste Curbelo, Mario Javier Halfon, Juan Ignacio Rojas, Berenice A. Silva, Vladimiro Sinay, Santiago Tizio, Maria Celica Ysrraelit & Ricardo Alonso. (2021) Radiologically isolated syndrome: from biological bases to practical management. Neurological Sciences 42:4, pages 1335-1344.
Crossref
Crossref
Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier & Neil Goldfarb. (2020) Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 5:1, pages 23-34.
Crossref
Crossref
Birgit Bauer, Bernd Brockmeier, Virginia Devonshire, Arthur Charbonne, Daniela Wach & Barry Hendin. (2020) An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis. Neurodegenerative Disease Management 10:6, pages 369-382.
Crossref
Crossref
Eric Engebretson, Rebecca A. Seale, Brooke Valdez, Timothy L. Vollmer & Luis D. Medina. (2020) Validation of the functional assessment of chronic illness therapy – General treatment satisfaction (FACIT-TS-G) in multiple sclerosis. Multiple Sclerosis and Related Disorders 45, pages 102413.
Crossref
Crossref
Edward J. D. Webb, David Meads, Ieva Eskytė, Helen L. Ford, Hilary L. Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue H. Pavitt, Klaus Schmierer & Ana Manzano. (2020) The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. The Patient - Patient-Centered Outcomes Research 13:5, pages 583-597.
Crossref
Crossref
Jihad Said Inshasi, Abubaker Almadani, Sarmad Al Fahad, Suzan Ibrahim Noori, Taoufik Alsaadi, Mustafa Shakra, Ahmed Osman Shatila, Tayseer Mohammed Zein & Amir Boshra. (2020) High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegenerative Disease Management 10:4, pages 257-266.
Crossref
Crossref
Patrick Vermersch, Jiwon Oh, Mark Cascione, Celia Oreja-Guevara, Claudio Gobbi, Lori H. Travis, Kjell-Morten Myhr & Patricia K. Coyle. (2020) Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders 43, pages 102158.
Crossref
Crossref
L.A. Visser, C. Louapre, C.A. Uyl-de Groot & W.K. Redekop. (2020) Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 39, pages 101929.
Crossref
Crossref
Christine Poulos, Craig Wakeford, Elizabeth Kinter, Brennan Mange, Thomas Schenk & Mehul Jhaveri. (2020) Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:1, pages 205521732091077.
Crossref
Crossref
Natasha Frost, Jerome Freeman, Diana Brixner, Jane Mort, James Clem & Surachat Ngorsuraches. (2019) Patients’ preferences and willingness-to-pay for disease-modifying therapies. Multiple Sclerosis and Related Disorders 35, pages 55-60.
Crossref
Crossref
Daniel R. Wynn. (2019) Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. Multiple Sclerosis International 2019, pages 1-19.
Crossref
Crossref
Marco Kaufmann, Jens Kuhle, Milo A Puhan, Christian P Kamm, Andrew Chan, Anke Salmen, Jürg Kesselring, Pasquale Calabrese, Claudio Gobbi, Caroline Pot, Nina Steinemann, Stephanie Rodgers & Viktor von Wyl. (2018) Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881456.
Crossref
Crossref
Andrés Barboza. (2018) Suspensión de las terapias modificadoras de la enfermedad en esclerosis múltiple. Una aproximación multidimensional. Neurología Argentina 10:4, pages 232-240.
Crossref
Crossref
Edward J. D. Webb, David Meads, Ieva Eskyte, Natalie King, Naila Dracup, Jeremy Chataway, Helen L. Ford, Joachim Marti, Sue H. Pavitt, Klaus Schmierer & Ana Manzano. (2018) A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. The Patient - Patient-Centered Outcomes Research 11:4, pages 391-402.
Crossref
Crossref